Chronic Diseases and Translational Medicine最新文献

Tislelizumab is a next-generation PD-1 monoclonal antibody developed to overcome the limitations of earlier immune checkpoint inhibitors. By eliminating Fcγ receptor binding, it avoids macrophage-mediated T-cell clearance and enhances the antitumor immune response. Unlike conventional PD-1 inhibitors, tislelizumab binds to PD-1 in a way that more closely mimics the natural PD-L1 interaction, potentially improving efficacy and reducing immune-related toxicity. This review highlights its structural advantages, clinical efficacy across multiple cancers, and recent global regulatory approvals. We also discuss key pharmacokinetic features and current challenges, including the need for predictive biomarkers, immune-related adverse events, and combination therapy strategies. Together, these insights may guide the more effective and safer use of tislelizumab in cancer immunotherapy.

The global burden of diabetes mellitus disproportionately affects low- and middle-income countries (LMICs), where limited healthcare infrastructure hampers timely and effective disease management. Wearable technologies, such as continuous glucose monitors (CGMs), insulin pumps, and fitness trackers, offer a transformative opportunity to bridge care gaps by enabling real-time monitoring, personalized feedback, and improved glycemic control. Evidence shows how wearables enhance patient engagement, support clinical decision-making, and reduce complications. However, significant barriers such as cost, digital illiteracy, poor system integration, and data privacy concerns impede widespread adoption in LMICs. Case studies from Ghana, China, and Ethiopia illustrate these devices' potential and challenges in resource-limited settings. Policy interventions, such as public-private partnerships, subsidies, simplified interfaces, and digital literacy programs, are essential to overcome these obstacles. Furthermore, integrating wearable data into national health systems and leveraging artificial intelligence can improve individualized care and long-term outcomes. As mobile phone use increases in LMICs, coupling wearables with mHealth platforms could further empower self-management. With targeted investments and regulatory support, wearable technologies can be pivotal in advancing equitable, proactive, and data-driven diabetes care across underserved populations.

S. Lehrer and P. H. Rheinstein, “Association of Cannabis With Chronic Obstructive Pulmonary Disease and COVID-19 Infection,” Chronic Diseases and Translational Medicine 8 (2022): 238–241, https://doi.org/10.1002/cdt3.38.

The original article included a Conflict of Interest statement which stated: “The authors declare no conflicts of interest.” The journal and the publisher have determined that a conflict of interest on behalf of each author was not declared at publication. The journal and the publisher have had sufficient communication with the authors via email after raising questions about the Conflict of Interest in the article. The authors declared that there was no undeclared Conflict of Interest and further stated that their individual affiliations with commercial entities did not influence the research findings. Following further correspondence between the publisher and the authors, all parties have agreed to include the following Conflicts of Interest statement with the published article.

Conflicts of Interest

Steven Lehrer serves in a scientific advisory capacity with Fermata Pharma, Inc. Peter H. Rheinstein is President of Severn Health Solutions. The scientific content was developed without influence from Fermata Pharma Inc. or Severn Health Solutions.

S. Lehrer and P. H. Rheinstein, “Shingles Vaccination Reduces the Risk of Parkinson's Disease,” Chronic Diseases and Translational Medicine 9 (2023): 54−57, https://doi.org/10.1002/cdt3.50.

The original article included a Conflict of Interest statement which stated: “The authors declare no conflicts of interest.” The journal and the publisher have determined that a conflict of interest on behalf of each author was not declared at publication. The journal and the publisher have had sufficient communication with the authors via email after raising questions about the Conflict of Interest in the article. The authors declared that there was no undeclared Conflict of Interest and further stated that their individual affiliations with commercial entities did not influence the research findings. Following further correspondence between the publisher and the authors, all parties have agreed to include the following Conflicts of Interest statement with the published article.

Conflicts of Interest

Steven Lehrer serves in a scientific advisory capacity with Fermata Pharma, Inc. Peter H. Rheinstein is President of Severn Health Solutions. The scientific content was developed without influence from Fermata Pharma Inc. or Severn Health Solutions.